Gossamer Bio, Inc. (GOSS)
NASDAQ
Real-time Data
01:30 PM
Day's Range
11.3552 wk Range
9.12Overview - GOSS - Gossamer Bio, Inc.
Key Statistics
Valuation
Enterprise Value
56.00M
P/E (Trailing)
‪-0.18‬
P/E (Forward)
‪-0.77‬
PEG Ratio
‪0.000073‬
Price / Sales (TTM)
‪1.39‬
Price / Book
‪-0.46‬
EV / EBITDA
‪-0.35‬
Profitability
Profit Margin
‪-235.00%‬
Operating Margin
‪-282.24%‬
Return on Assets
‪-62.39%‬
Return on Equity
‪138.78%‬
Ownership
Shares Outstanding
6.11M
Float
3.83M
Short % of Shares Outstanding
‪0.21%‬
Held by Insiders
‪1.43%‬
Held by Institutions
‪85.77%‬
Price stats
Beta
‪2.00‬
50-Day Avg
‪13.18‬
200-Day Avg
‪78.80‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
7 analysts
Average price target
‪$ 1.66‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - GOSS - Gossamer Bio, Inc.
Peers - GOSS - Gossamer Bio, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- GOSSNASDAQGossamer Bio, Inc.65.62MMarket Cap-2256.01%52-week change-0.18P/E (Trailing)‪-235.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - GOSS - Gossamer Bio, Inc.
About
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious cardiopulmonary and immune-mediated diseases. Its lead program is seralutinib, an investigational inhaled therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
